A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: How can compliance be improved?

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 19, Issue 4, 2006, Pages 221-224

  Pignotti, Maria Serenella ^a   Catarzi, Serena ^a   Donzelli, Gianpaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Compliance; Newborn; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; BREATHING MUSCLE; CHILD; DRUG TOLERANCE; FEMALE; HEALTH SURVEY; HIGH RISK INFANT; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; OXYGEN THERAPY; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIRTH WEIGHT; COMMUNICATION BARRIERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; PATIENT COMPLIANCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 33745714799     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050600591290     Document Type: Article

References (9)

1. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
2. Groothuis JR, for the Northern Hemisphere Expanded Access Study Group. Safety and tolerance of palivizumab administration in a large northern hemisphere trial. Pediatr Infect Dis J 2001;20:628-630.
3. Sorrentino M, Powers T, and the Outcomes Study Group. Effectiveness of palivizumab: Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J 2000;19:1068-1071.
4. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: Indications for the use of and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-1216.
5. Società Italiana di Pediatria Raccomandazioni per la prevenzione della malattia da Virus Respiratorio Sinciziale (RSV). Italian Journal of Pediatrics 2000;26:379-381.
6. American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-1446.
7. Consiglio direttivo della Società Italiana di Neonatologia. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Aggiornamento 2004. Acta Neonatologica e Pediatrica 2004;1:19-29.
8. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM. Cardiac Synagis Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-540.
9. Pignotti MS, Indolfi G, Donzelli GP. Factors impacting compliance with palivizumab prophylaxis. Pediatr Infect Dis J 2004;23:186-187.